Bain Capital Life Sciences Investors as of June 30, 2022
Portfolio Holdings for Bain Capital Life Sciences Investors
Bain Capital Life Sciences Investors holds 35 positions in its portfolio as reported in the June 2022 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Springworks Therapeutics (SWTX) | 13.9 | $119M | 4.8M | 24.62 | |
| Dynavax Technologies Corp Com New (DVAX) | 12.4 | $106M | 8.4M | 12.59 | |
| Pharvaris N V (PHVS) | 8.2 | $70M | 3.2M | 22.10 | |
| Arcutis Biotherapeutics (ARQT) | 7.5 | $64M | 3.0M | 21.31 | |
| Eqrx | 5.5 | $47M | 10M | 4.69 | |
| Nuvalent Inc-a (NUVL) | 5.5 | $47M | 3.4M | 13.56 | |
| Crinetics Pharmaceuticals In (CRNX) | 5.0 | $43M | 2.3M | 18.65 | |
| Mersana Therapeutics (MRSN) | 4.7 | $40M | 8.7M | 4.62 | |
| Amylyx Pharmaceuticals (AMLX) | 4.4 | $38M | 1.9M | 19.26 | |
| Rapid Micro Biosystems Class A Com (RPID) | 4.3 | $36M | 8.4M | 4.30 | |
| Cara Therapeutics (CARA) | 2.8 | $24M | 2.6M | 9.13 | |
| Nurix Therapeutics (NRIX) | 2.7 | $23M | 1.8M | 12.67 | |
| 2seventy Bio Common Stock (TSVT) | 2.2 | $19M | 1.4M | 13.20 | |
| Protagonist Therapeutics (PTGX) | 2.1 | $18M | 2.3M | 7.91 | |
| Savara (SVRA) | 2.1 | $18M | 12M | 1.52 | |
| Atea Pharmaceuticals (AVIR) | 2.1 | $18M | 2.5M | 7.10 | |
| C4 Therapeutics Com Stk (CCCC) | 1.5 | $12M | 1.6M | 7.54 | |
| Annexon (ANNX) | 1.4 | $12M | 3.2M | 3.77 | |
| Research Alliance Corp Ii Com Cl A | 1.1 | $9.8M | 1.0M | 9.80 | |
| Tango Therapeutics (TNGX) | 1.0 | $8.7M | 1.9M | 4.53 | |
| ACADIA Pharmaceuticals (ACAD) | 1.0 | $8.5M | 601k | 14.09 | |
| Xilio Therapeutics (XLO) | 1.0 | $8.2M | 2.8M | 2.92 | |
| Marinus Pharmaceuticals Com New (MRNS) | 0.8 | $6.9M | 1.4M | 4.84 | |
| Arya Sciences Acqu Corp Iv Cl A (ARYD) | 0.8 | $6.9M | 700k | 9.81 | |
| Adagio Therapeutics (IVVD) | 0.7 | $6.4M | 1.9M | 3.28 | |
| Syros Pharmaceuticals | 0.7 | $6.0M | 6.3M | 0.96 | |
| Nautilus Biotechnology (NAUT) | 0.6 | $5.4M | 2.0M | 2.69 | |
| Aptinyx | 0.6 | $5.0M | 8.9M | 0.56 | |
| Solid Biosciences | 0.6 | $4.9M | 7.9M | 0.62 | |
| Panacea Acquisition Corp Ii Cl A Shs | 0.6 | $4.9M | 500k | 9.76 | |
| Arya Sciences Acquisitn Corp Class A Ord Shs | 0.6 | $4.9M | 500k | 9.72 | |
| Bcls Acquisition Corp Com Cl A | 0.6 | $4.8M | 488k | 9.90 | |
| Frazier Lifesciences Acqu Unit 12/09/2025 | 0.3 | $3.0M | 300k | 9.87 | |
| X4 Pharmaceuticals (XFOR) | 0.3 | $2.9M | 3.0M | 0.96 | |
| Aeglea Biotherapeutics | 0.3 | $2.7M | 5.3M | 0.51 |
